Analysts Expect Seres Therapeutics Inc (MCRB) Will Post Earnings of -$0.73 Per Share

Wall Street analysts expect Seres Therapeutics Inc (NASDAQ:MCRB) to post earnings of ($0.73) per share for the current quarter, according to Zacks. Three analysts have made estimates for Seres Therapeutics’ earnings, with estimates ranging from ($0.79) to ($0.68). Seres Therapeutics posted earnings per share of ($0.63) in the same quarter last year, which suggests a negative year-over-year growth rate of 15.9%. The firm is scheduled to report its next quarterly earnings results on Thursday, March 15th.

According to Zacks, analysts expect that Seres Therapeutics will report full year earnings of ($2.33) per share for the current year, with EPS estimates ranging from ($2.78) to ($2.18). For the next financial year, analysts expect that the firm will report earnings of ($2.67) per share, with EPS estimates ranging from ($2.97) to ($2.48). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover Seres Therapeutics.

A number of research firms have recently issued reports on MCRB. BidaskClub cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, February 7th. Zacks Investment Research cut shares of Seres Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, January 10th. Three analysts have rated the stock with a sell rating and nine have given a buy rating to the company’s stock. Seres Therapeutics has an average rating of “Buy” and a consensus target price of $18.00.

Hedge funds have recently added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new position in shares of Seres Therapeutics during the 3rd quarter worth about $2,165,000. Northern Trust Corp lifted its position in Seres Therapeutics by 16.2% in the 2nd quarter. Northern Trust Corp now owns 235,766 shares of the biotechnology company’s stock valued at $2,664,000 after acquiring an additional 32,875 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Seres Therapeutics by 39.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 373,334 shares of the biotechnology company’s stock valued at $6,160,000 after acquiring an additional 106,479 shares in the last quarter. Lakeview Capital Partners LLC bought a new position in Seres Therapeutics in the 4th quarter valued at about $346,000. Finally, State Street Corp lifted its position in Seres Therapeutics by 12.0% in the 2nd quarter. State Street Corp now owns 321,699 shares of the biotechnology company’s stock valued at $3,637,000 after acquiring an additional 34,393 shares in the last quarter. 81.78% of the stock is currently owned by institutional investors.

Seres Therapeutics (MCRB) traded up $0.01 during mid-day trading on Friday, hitting $9.43. 87,200 shares of the stock were exchanged, compared to its average volume of 140,780. The company has a market cap of $381.79, a PE ratio of -4.45 and a beta of 0.24. The company has a quick ratio of 6.53, a current ratio of 6.53 and a debt-to-equity ratio of 0.11. Seres Therapeutics has a one year low of $7.90 and a one year high of $17.42.

TRADEMARK VIOLATION NOTICE: This report was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another site, it was copied illegally and reposted in violation of United States & international trademark & copyright laws. The correct version of this report can be viewed at https://stocknewstimes.com/2018/02/21/analysts-expect-seres-therapeutics-inc-mcrb-will-post-earnings-of-0-73-per-share.html.

About Seres Therapeutics

Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply